Furthermore, in vivo testing in a xenograft model of TNBC shows enhanced tumor activity and survival in mice treated with the PD-L1-targeted NIC to both drugs given in combination, suggesting effective PD-L1 targeting. Here, CD274 is linked to neoplasm.